Uveal melanoma (UM) is a rare malignancy that arises from melanocytes within the uveal tract of the eye.

1. Uveal Melanoma - Market Insights,
Epidemiology, & Market Forecast
2027
DelveInsight © 2018 | All rights reserved

2. Uveal
melanoma
(UM) is a rare
malignancy
that arises from
melanocytes
within the
uveal tract of
the eye
Uveal
melanoma
(UM) is the
most common
intraocular
malignancy and
arises from
melanocytes in
the iris, ciliary
body, or
choroid
Most Uveal
melanomas
are initially
completely a
symptomatic.
As the tumor enlarges,
it may cause distortion
of the pupil (iris
melanoma), blurred
vision (Ciliary body
melanoma), or
markedly decreased
visual acuity caused by
secondary retinal
detachment (choroidal
melanoma).
Introduction Uveal Melanoma :
DelveInsight © 2018 | All rights reserved

3. The diagnostic error rate in the
Collaborative Ocular
Melanoma Study (COMS) was
only 0.48%.
The diagnostic error rate in the
COMS, however, was measured
under ideal conditions; all
tumors were well visualized
and photographed.
Misdiagnoses occur in less than
4% of enucleated eyes at
tertiary referral centers.
In real-world situations, the
misdiagnosis rate for
posterior melanoma may be
greater than that reported by
the Collaborative Ocular
Melanoma Study
DIAGNOSIS
DelveInsight © 2018 | All rights reserved

4. Aspects Covered in the Report
01
03
04 02
05
The report also reviews the
detailed historical and
forecasted Uveal Melanoma
market size covering the drug
outreach in 7MM
The report is a comprehensive account
of both the current and emerging
therapies covering the impact of the
new therapies on the current
treatment landscape
The report provides the
understanding of the
future competition in
Uveal Melanoma by
reviewing the market
drivers and barriers
The report covers the
descriptive overview of Uveal
Melanoma explaining its
pathophysiology, disease
classification, diagnostic
approaches and treatment
algorithm
The report provides the
insight into the epidemiology
of the disease and its
treatment in the 7 MM
DelveInsight © 2018 | All rights reserved

5. BVD-523
Light activated
AU-011
Crizotinib
Melphalan
IMCgp100
Selumetinib
Emerging Drugs And Companies
DelveInsight © 2018 | All rights reserved

6. Market Insight
DelveInsight © 2018 | All rights reserved
Despite usual success in
achieving local control,
outcomes for patients with
metastatic disease remains
impoverished.
h
Despite of Uveal Melanoma’s effective primary
therapy, nearly 50% of patients develop
metastatic disease.
Several palliative treatments for UM
offered in the US and Europe
include Liverdirected treatments-
Trans arterial Catheter and
Immunotherapy, targeted therapy.
As per National Cancer Institute, the
mean age-adjusted incidence of Uveal
melanoma in the United States is
approximately xxx new cases per million
people, with no clear variation by latitude

7. Complete Information
For complete information please click below
Or
write to us at
info@delveinsight.com
DelveInsight © 2018 | All rights reserved
Click here

8. About Delveinsight
Vision
“Insight across the
value chain” to help
organizations make
important business
decisions through the
use and analysis of
actionable market
intelligence.
DelveInsight © 2018 | All rights reserved

9. Asset Prioritization
Brand Optimization
Portfolio expansion
access over 3000+
reports
Therapeutic
Assessment
Drug Sales
Forecast
Indication Forecast
Clinical Trials
Tracking
Competitive
landscape
Clinical Trials
Trends Analysis
Physicians &
Patients
Perception
KOLs
API
Market &
Pipeline
Epidemiology
Market
Access
Partnership
Services Offered at DelveInsight
DelveInsight © 2018 | All rights reserved

10. DelveInsight © 2018 | All rights reserved
Contact Us:
info@delveinsight.com
+91-11-4568 9769
www.delveinsight.com
blog/delveInsight/
twitter/delveInsight
LinkedIn/delveInsight